TruScreen Share Price: A 2-Cent Bet on AI Cervical Cancer Screening Going Global
TruScreen Share Price Today
The TruScreen share price sits at about $0.019 NZD (NZX: TRU) in mid-June 2026, roughly flat over the past year. With a market cap near $16 million, TruScreen is a dual NZX and ASX-listed medical-technology company commercialising an AI-enabled device for cervical-cancer screening. It is a classic early-stage medtech story: a promising technology, fast sales growth, big addressable markets, and ongoing losses.
The appeal is the mission and the market size; the risk is that, like many small medtechs, it is still some way from sustained profitability.
What TruScreen Does
TruScreen has developed a real-time, AI-enabled device that detects pre-cancerous and cancerous changes of the cervix without the need for a laboratory. That is potentially valuable in markets that lack the infrastructure for conventional lab-based screening, which is why TruScreen has focused on large emerging markets. It now distributes across around 20 countries, including three of the world's four most populous nations: China, India, and Indonesia.
This is a different kind of healthcare business from NZ's care operators, more comparable to cancer-diagnostics firm Pacific Edge and pharmaceutical company AFT Pharmaceuticals, where the value hinges on clinical validation, regulatory approvals, and adoption.
Recent Performance: Fast Growth, Still Lossmaking
TruScreen's preliminary FY26 result showed encouraging momentum:
- •Product sales up about 42% year on year, its fastest commercial expansion in recent years
- •Growth driven by new market entries in India and Indonesia plus continued growth elsewhere
- •Important clinical and endorsement progress in China, including a study validating its use and an anticipated expert consensus endorsement from a Chinese cervical-pathology body
The 42% sales growth is genuinely positive, but the company remains lossmaking, hence the negative P/E and the need for funding initiatives. The investment case rests on that growth continuing until the business reaches profitable scale.
Key Metrics
- •Share price: ~$0.019 NZD
- •Market cap: ~$16 million NZD
- •52-week move: about flat
- •Product sales growth: ~42%
- •P/E ratio: not meaningful (lossmaking)
- •Net tangible assets: ~$0.003 per share
- •Gross dividend yield: 0%
What to Watch
- •China endorsement and adoption: Formal clinical endorsement in China is a potentially major catalyst given the market's size. Watch for it and for actual sales follow-through.
- •Sustained sales growth: 42% growth is the bull case in action. The key is whether it continues across India, Indonesia, and beyond.
- •Path to profit and funding: TruScreen is lossmaking and has pursued funding. Watch the cash position and dilution risk.
- •Regulatory approvals: New market entries depend on clearances. Each approval expands the opportunity.
The Bottom Line
TruScreen is an early-stage medtech with a clinically meaningful cervical-cancer screening device, rapid sales growth, and exposure to enormous emerging markets. The bull case is a validated technology scaling across China, India, and Indonesia toward profitability, with a potential China endorsement as a catalyst. The bear case is the familiar medtech reality: still lossmaking, dependent on regulatory and clinical milestones, and reliant on funding that dilutes holders. This is a speculative growth stock for risk-tolerant investors who believe TruScreen can convert its sales momentum into sustained profit.
For how we evaluate early-stage medtech, see our methodology.
*Disclaimer: This article is for educational and informational purposes only. It does not constitute financial advice. Stock data may not be real-time. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.*